Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness

Franziska Severin; Pascal Borry; Martina C Cornel; Norman Daniels; Florence Fellmann; Shirley Victoria Hodgson; Heidi C Howard; Jürgen John; Helena Kääriäinen; Hülya Kayserili; Alastair Kent; Florian Koerber; Ulf Kristoffersson; Mark Kroese; Celine Lewis; Georg Marckmann; Peter Meyer; Arne Pfeufer; Jörg Schmidtke; Heather Skirton; Lisbeth Tranebjærg; Wolf H Rogowski

doi:10.1038/ejhg.2014.190

Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness

Franziska Severin, Pascal Borry, Martina C Cornel, Norman Daniels, Florence Fellmann, Shirley Victoria Hodgson, Heidi C Howard, Jürgen John, Helena Kääriäinen, Hülya Kayserili, Alastair Kent, Florian Koerber, Ulf Kristoffersson, Mark Kroese, Celine Lewis, Georg Marckmann, Peter Meyer, Arne Pfeufer, Jörg Schmidtke, Heather SkirtonLisbeth Tranebjærg, Wolf H Rogowski

19 Citationer (Scopus)

Abstract

Given the cost constraints of the European health-care systems, criteria are needed to decide which genetic services to fund from the public budgets, if not all can be covered. To ensure that high-priority services are available equitably within and across the European countries, a shared set of prioritization criteria would be desirable. A decision process following the accountability for reasonableness framework was undertaken, including a multidisciplinary EuroGentest/PPPC-ESHG workshop to develop shared prioritization criteria. Resources are currently too limited to fund all the beneficial genetic testing services available in the next decade. Ethically and economically reflected prioritization criteria are needed. Prioritization should be based on considerations of medical benefit, health need and costs. Medical benefit includes evidence of benefit in terms of clinical benefit, benefit of information for important life decisions, benefit for other people apart from the person tested and the patient-specific likelihood of being affected by the condition tested for. It may be subject to a finite time window. Health need includes the severity of the condition tested for and its progression at the time of testing. Further discussion and better evidence is needed before clearly defined recommendations can be made or a prioritization algorithm proposed. To our knowledge, this is the first time a clinical society has initiated a decision process about health-care prioritization on a European level, following the principles of accountability for reasonableness. We provide points to consider to stimulate this debate across the EU and to serve as a reference for improving patient management.

Originalsprog	Engelsk
Tidsskrift	European Journal of Human Genetics
Vol/bind	23
Sider (fra-til)	1-7
Antal sider	7
ISSN	1018-4813
DOI	https://doi.org/10.1038/ejhg.2014.190
Status	Udgivet - 15 jun. 2015

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/ejhg.2014.190Licens: CC BY-NC

Citationsformater

Severin, F., Borry, P., Cornel, M. C., Daniels, N., Fellmann, F., Victoria Hodgson, S., Howard, H. C., John, J., Kääriäinen, H., Kayserili, H., Kent, A., Koerber, F., Kristoffersson, U., Kroese, M., Lewis, C., Marckmann, G., Meyer, P., Pfeufer, A., Schmidtke, J., ... Rogowski, W. H. (2015). Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness. European Journal of Human Genetics, 23, 1-7. https://doi.org/10.1038/ejhg.2014.190

Severin, F, Borry, P, Cornel, MC, Daniels, N, Fellmann, F, Victoria Hodgson, S, Howard, HC, John, J, Kääriäinen, H, Kayserili, H, Kent, A, Koerber, F, Kristoffersson, U, Kroese, M, Lewis, C, Marckmann, G, Meyer, P, Pfeufer, A, Schmidtke, J, Skirton, H, Tranebjærg, L & Rogowski, WH 2015, 'Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness', European Journal of Human Genetics, bind 23, s. 1-7. https://doi.org/10.1038/ejhg.2014.190

@article{fe13925ec0f94cd5b85939eaec42f903,

title = "Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness",

abstract = "Given the cost constraints of the European health-care systems, criteria are needed to decide which genetic services to fund from the public budgets, if not all can be covered. To ensure that high-priority services are available equitably within and across the European countries, a shared set of prioritization criteria would be desirable. A decision process following the accountability for reasonableness framework was undertaken, including a multidisciplinary EuroGentest/PPPC-ESHG workshop to develop shared prioritization criteria. Resources are currently too limited to fund all the beneficial genetic testing services available in the next decade. Ethically and economically reflected prioritization criteria are needed. Prioritization should be based on considerations of medical benefit, health need and costs. Medical benefit includes evidence of benefit in terms of clinical benefit, benefit of information for important life decisions, benefit for other people apart from the person tested and the patient-specific likelihood of being affected by the condition tested for. It may be subject to a finite time window. Health need includes the severity of the condition tested for and its progression at the time of testing. Further discussion and better evidence is needed before clearly defined recommendations can be made or a prioritization algorithm proposed. To our knowledge, this is the first time a clinical society has initiated a decision process about health-care prioritization on a European level, following the principles of accountability for reasonableness. We provide points to consider to stimulate this debate across the EU and to serve as a reference for improving patient management.",

author = "Franziska Severin and Pascal Borry and Cornel, {Martina C} and Norman Daniels and Florence Fellmann and {Victoria Hodgson}, Shirley and Howard, {Heidi C} and J{\"u}rgen John and Helena K{\"a}{\"a}ri{\"a}inen and H{\"u}lya Kayserili and Alastair Kent and Florian Koerber and Ulf Kristoffersson and Mark Kroese and Celine Lewis and Georg Marckmann and Peter Meyer and Arne Pfeufer and J{\"o}rg Schmidtke and Heather Skirton and Lisbeth Tranebj{\ae}rg and Rogowski, {Wolf H}",

year = "2015",

month = jun,

day = "15",

doi = "10.1038/ejhg.2014.190",

language = "English",

volume = "23",

pages = "1--7",

journal = "European Journal of Human Genetics",

issn = "1018-4813",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Points to consider for prioritizing clinical genetic testing services

T2 - a European consensus process oriented at accountability for reasonableness

AU - Severin, Franziska

AU - Borry, Pascal

AU - Cornel, Martina C

AU - Daniels, Norman

AU - Fellmann, Florence

AU - Victoria Hodgson, Shirley

AU - Howard, Heidi C

AU - John, Jürgen

AU - Kääriäinen, Helena

AU - Kayserili, Hülya

AU - Kent, Alastair

AU - Koerber, Florian

AU - Kristoffersson, Ulf

AU - Kroese, Mark

AU - Lewis, Celine

AU - Marckmann, Georg

AU - Meyer, Peter

AU - Pfeufer, Arne

AU - Schmidtke, Jörg

AU - Skirton, Heather

AU - Tranebjærg, Lisbeth

AU - Rogowski, Wolf H

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Given the cost constraints of the European health-care systems, criteria are needed to decide which genetic services to fund from the public budgets, if not all can be covered. To ensure that high-priority services are available equitably within and across the European countries, a shared set of prioritization criteria would be desirable. A decision process following the accountability for reasonableness framework was undertaken, including a multidisciplinary EuroGentest/PPPC-ESHG workshop to develop shared prioritization criteria. Resources are currently too limited to fund all the beneficial genetic testing services available in the next decade. Ethically and economically reflected prioritization criteria are needed. Prioritization should be based on considerations of medical benefit, health need and costs. Medical benefit includes evidence of benefit in terms of clinical benefit, benefit of information for important life decisions, benefit for other people apart from the person tested and the patient-specific likelihood of being affected by the condition tested for. It may be subject to a finite time window. Health need includes the severity of the condition tested for and its progression at the time of testing. Further discussion and better evidence is needed before clearly defined recommendations can be made or a prioritization algorithm proposed. To our knowledge, this is the first time a clinical society has initiated a decision process about health-care prioritization on a European level, following the principles of accountability for reasonableness. We provide points to consider to stimulate this debate across the EU and to serve as a reference for improving patient management.

AB - Given the cost constraints of the European health-care systems, criteria are needed to decide which genetic services to fund from the public budgets, if not all can be covered. To ensure that high-priority services are available equitably within and across the European countries, a shared set of prioritization criteria would be desirable. A decision process following the accountability for reasonableness framework was undertaken, including a multidisciplinary EuroGentest/PPPC-ESHG workshop to develop shared prioritization criteria. Resources are currently too limited to fund all the beneficial genetic testing services available in the next decade. Ethically and economically reflected prioritization criteria are needed. Prioritization should be based on considerations of medical benefit, health need and costs. Medical benefit includes evidence of benefit in terms of clinical benefit, benefit of information for important life decisions, benefit for other people apart from the person tested and the patient-specific likelihood of being affected by the condition tested for. It may be subject to a finite time window. Health need includes the severity of the condition tested for and its progression at the time of testing. Further discussion and better evidence is needed before clearly defined recommendations can be made or a prioritization algorithm proposed. To our knowledge, this is the first time a clinical society has initiated a decision process about health-care prioritization on a European level, following the principles of accountability for reasonableness. We provide points to consider to stimulate this debate across the EU and to serve as a reference for improving patient management.

U2 - 10.1038/ejhg.2014.190

DO - 10.1038/ejhg.2014.190

M3 - Journal article

C2 - 25248395

SN - 1018-4813

VL - 23

SP - 1

EP - 7

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

ER -

Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater